scholarly journals Production of High Value Amine Intermediates via Biocatalytic Cascades in Continuous Flow

Author(s):  
Ashley P. Mattey ◽  
grayson ford ◽  
Joan Citoler ◽  
Christopher Baldwin ◽  
James Marshall ◽  
...  

<div> <p>A key aim of biocatalysis is to mimic the ability of eukaryotic cells to carry out compartmentalized multistep cascades in a controlled and selective way. As biocatalytic cascades get longer and more complex, reactions become unattainable under typical batch conditions. Here a continuous flow multipoint injection reactor was combined with switching valves to overcome batch incompatibility, thus allowing for successful biocatalytic reaction cascades. As proof-of-principle, several reactive carbonyl intermediates were generated <i>in situ </i>using galactose oxidase and engineered choline oxidases, then passed directly to a series of packed-bed modules containing different aminating biocatalysts which accordingly produced a range of structurally distinct amines. The method was expanded to employ a batch incompatible sequential amination cascade <i>via </i>an oxidase-transaminase-imine reductase sequence, introducing different amine reagents at each step without cross reactivity. The combined approaches allowed for the biocatalytic synthesis of the natural product alkaloid precursor 4O-methylnorbelladine. The flow biocatalysis platform shown here significantly increases the scope of novel biocatalytic cascades, removing previous limitations due to reaction and reagent batch incompatibility.</p> </div> <b><br></b>

2021 ◽  
Author(s):  
Ashley P. Mattey ◽  
grayson ford ◽  
Joan Citoler ◽  
Christopher Baldwin ◽  
James Marshall ◽  
...  

<div> <p>A key aim of biocatalysis is to mimic the ability of eukaryotic cells to carry out compartmentalized multistep cascades in a controlled and selective way. As biocatalytic cascades get longer and more complex, reactions become unattainable under typical batch conditions. Here a continuous flow multipoint injection reactor was combined with switching valves to overcome batch incompatibility, thus allowing for successful biocatalytic reaction cascades. As proof-of-principle, several reactive carbonyl intermediates were generated <i>in situ </i>using galactose oxidase and engineered choline oxidases, then passed directly to a series of packed-bed modules containing different aminating biocatalysts which accordingly produced a range of structurally distinct amines. The method was expanded to employ a batch incompatible sequential amination cascade <i>via </i>an oxidase-transaminase-imine reductase sequence, introducing different amine reagents at each step without cross reactivity. The combined approaches allowed for the biocatalytic synthesis of the natural product alkaloid precursor 4O-methylnorbelladine. The flow biocatalysis platform shown here significantly increases the scope of novel biocatalytic cascades, removing previous limitations due to reaction and reagent batch incompatibility.</p> </div> <b><br></b>


1985 ◽  
Vol 50 (10) ◽  
pp. 2122-2133 ◽  
Author(s):  
Jindřich Zahradník ◽  
Marie Fialová ◽  
Jan Škoda ◽  
Helena Škodová

An experimental study was carried out aimed at establishing a data base for an optimum design of a continuous flow fixed-bed reactor for biotransformation of ammonium fumarate to L-aspartic acid catalyzed by immobilized cells of the strain Escherichia alcalescens dispar group. The experimental program included studies of the effect of reactor geometry, catalytic particle size, and packed bed arrangement on reactor hydrodynamics and on the rate of substrate conversion. An expression for the effective reaction rate was derived including the effect of mass transfer and conditions of the safe conversion-data scale-up were defined. Suggestions for the design of a pilot plant reactor (100 t/year) were formulated and decisive design parameters of such reactor were estimated for several variants of problem formulation.


Hydrobiologia ◽  
1989 ◽  
Vol 188-189 (1) ◽  
pp. 277-283 ◽  
Author(s):  
C. Lindblad ◽  
U. Kautsky ◽  
C. André ◽  
N. Kautsky ◽  
M. Tedengren

ChemSusChem ◽  
2017 ◽  
Vol 10 (17) ◽  
pp. 3435-3444 ◽  
Author(s):  
Tamas Fodi ◽  
Christos Didaskalou ◽  
Jozsef Kupai ◽  
Gyorgy T. Balogh ◽  
Peter Huszthy ◽  
...  

2021 ◽  
Vol 9 (16) ◽  
pp. 5519-5525
Author(s):  
Michael Prieschl ◽  
Sándor B. Ötvös ◽  
C. Oliver Kappe

1998 ◽  
Vol 111 (2) ◽  
pp. 171-181 ◽  
Author(s):  
L. Lafanechere ◽  
C. Courtay-Cahen ◽  
T. Kawakami ◽  
M. Jacrot ◽  
M. Rudiger ◽  
...  

The C terminus of the tubulin alpha-subunit of most eukaryotic cells undergoes a cycle of tyrosination and detyrosination using two specific enzymes, a tubulin tyrosine ligase (TTL) and a tubulin carboxypeptidase. Although this enzyme cycle is conserved in evolution and exhibits rapid turnover, the meaning of this modification has remained elusive. We have isolated several NIH-3T3 derived clonal cell lines that lack TTL (TTL-). TTL- cells contain a unique tubulin isotype (delta2-tubulin) that can be detected with specific antibodies. When injected into nude mice, both TTL- cells and TTL- cells stably transfected with TTL cDNA form sarcomas. But in tumors formed from TTL rescued cells, TTL is systematically lost during tumor growth. A strong selection process has thus acted during tumor growth to suppress TTL activity. In accord with this result, we find suppression of TTL activity in the majority of human tumors assayed with delta2-tubulin antibody. We conclude there is a widespread loss of TTL activity during tumor growth in situ, suggesting that TTL activity may play a role in tumor cell regulation.


Author(s):  
Jessica Orrego‐Hernández ◽  
Helen Hölzel ◽  
Maria Quant ◽  
Zhihang Wang ◽  
Kasper Moth‐Poulsen

2011 ◽  
Vol 52 (2) ◽  
pp. 263-265 ◽  
Author(s):  
Christopher B. Kelly ◽  
Christopher (Xiang) Lee ◽  
Nicholas E. Leadbeater

Sign in / Sign up

Export Citation Format

Share Document